If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-02. Numbers and descriptions here follow the published literature rather than marketing material.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
=== COVID-19 therapy === In a phase III study on the treatment of severe courses of COVID-19, sabizabulin reduced mortality by 55% according to the manufacturer. Because of the high efficacy, the test phase was stopped prematurely so that the drug no longer had to be withheld from the placebo control group.
fuels, materials, active pharmaceutical ingredients) and the discovery of new riboflavin cofactors. He has supervised about 70 students for the degree of Doctor of Philosophy, as well as about 60 postdoctoral research workers. He has published over 500 research papers and several patents. In 2015, Scrutton co-founded the company C3 Biotechnologies Ltd to commercialise technologies for chemicals, fuels and materials production. He was founding Director of the Manchester Synthetic Biology Research Centre SYNBIOCHEM, which he established in 2014 following major investment by the UK government in synthetic biology. In 2019, he established and became Director of the UK Future Biomanufacturing Research Hub, which is developing new technologies to accelerate bio-based manufacturing in the UK in three key sectors – pharmaceuticals, chemicals and engineering materials. He has served on several national committees, including research council / funding committees (BBSRC, EPSRC, Royal Society) and strategic advisory boards / scientific steering groups (e.g. Science and Technology Facilities Council). He is a former member of BBSRC Council (2021-24). While serving as Director, the MIB was awarded the Queen's Anniversary Prize for Higher and Further Education (2018–20).
Mechanical properties of cellulose in primary plant cell wall are correlated with growth and expansion of plant cells. Live fluorescence microscopy techniques are promising in investigation of the role of cellulose in growing plant cells.
== Contraindications == Contraindications of sumatriptan include history of coronary artery disease (atherosclerosis) or coronary artery vasospasm, Wolff–Parkinson–White syndrome or other cardiac accessory conduction pathway disorders, history of stroke, transient ischemic attack, or hemiplegic or basilar migraine, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, use of another triptan or ergot-related medication within the last 24 hours, concomitant or recent use of a monoamine oxidase inhibitor (MAOI), hypersensitivity to sumatriptan, and severe hepatic impairment.
Sources: en.wikipedia.org
=== Food products === In 1909, Ajinomoto Co. Inc. released its umami seasoning AJI-NO-MOTO, made from molasses and tapioca starch derived from sugarcane. In Asia and Latin America, the product was primarily sold to consumers, while in North America and Europe it was mostly sold to processed food manufacturers. In 1970, Ajinomoto launched the bonito flavored seasoning HON-DASHI in Japan, and later adapted the product to other markets with local flavors. In 1978 Ajinomoto released Cook Do, a series of Chinese cuisine seasoning products, and later added other cuisine seasoning flavors to the Cook Do product line. The company entered the frozen food business in 1972, and currently sells a variety of frozen food products, including dumplings, noodles, and cooked rice. In 1982, Ajinomoto Co., Inc. entered the sweetener business by producing aspartame. In 1984 it released a low-calorie consumer sweetener PAL SWEET. By 2021, Ajinomoto was ranked 6th overall and 1st in Asia on FoodTalks' Top 50 Global Sweetener Companies list. Ajinomoto Co., Inc. is the world's largest manufacturer of aspartame, sold under the trade name Aminosweet. Ajinomoto also sells soup, mayonnaise, porridge, pasta sauce, and instant noodles under the "VONO" brand name. Through Ajinomoto AGF Corporation, Ajinomoto sells instant coffee, regular coffee, bottled coffee, stick coffee, and canned coffee, and is the top coffee brand in Thailand with a 70% market share. Ajinomoto's Yum Yum brand of instant noodles in 2019 held a 20–21% share of Thailand's 17 billion baht instant noodle market.
=== 2011 === On May 19, 2011, Sharp in collaboration with NHK demonstrated a direct-view 85 inches (220 cm) LCD capable of 7680 × 4320 pixels at 10 bits per channel. It was the first direct-view Super Hi-Vision-compatible display released. Before 2011, UHDTV allowed for frame rates of 24, 25, 50, and 60 fps. In an ITU-R meeting during 2011, an additional frame rate was added to UHDTV of 120 fps.
== Rodlet self-assembly of class I hydrophobins == There is special interest in understanding the mechanism underlying class I monomers self-assembly that leads to formation of tough, ordered amphipathic rodlet monolayers, due to their intrinsic properties and due to substantial information available from several characterisation studies of the class I hydrophobins EAS and DewA. These mechanisms have been greatly studied by targeted mutagenesis in an effort to identify the key amino acid sequence regions driving rodlet self-assembly. A model for the monomeric form of EAS was proposed by Kwan et al. (2006) from structural data obtained from NMR spectroscopy and X-ray diffraction experiments that indicated the presence of four-stranded, antiparallel β-barrel core structure in EAS that allows monomer linking through backbone H-bonding. There are secondary elements around this β-barrel core like the Cys3-Cys4 and Cys7-Cys8 loops. This model is consistent with the amyloid-like structure that class I rodlets form, in which the β-strands are oriented perpendicular to the cross-β scaffold axis of the fibre. Site-directed mutagenesis of EAS has given insights into the specific structural changes responsible for self-assembly of monomers into rodlets and subsequent formation of amphipathic monolayer in hydrophobic:hydrophilic interfaces. Kwan et al.
Sources: en.wikipedia.org
PAD3 expression has been linked to sheep wool modification. Citrullination of trichohyalin allows it to bind and cross-link keratin filaments, directing growth of the wool fiber. PAD4 regulates gene expression through histone modifications. DNA is wrapped around histones, and the histone proteins can control DNA expression when chemical groups are added and removed. This process is known as post-translational processing or post-translational modification, because it takes place on the protein after the DNA is translated. The role of post-translational processing in gene regulation is the subject of the growing field of study, epigenetics. One modification mechanism is methylation. A methyl group binds to an arginine on the histone protein, altering DNA binding to the histone and allowing transcription to take place. When PAD converts arginine to citrulline on a histone, it blocks further methylation of the histone, inhibiting transcription. The main isotype for this is PAD4, which deiminates arginines and/or monomethylated arginines on histones 3 and 4, turning off the effects of arginine methylation.
=== Pharmacokinetics === Absorption of topical corticosteroids depends on several factors such as the vehicle, or delivery system used by the drug, the integrity of the epidermal barrier, and whether or not an occlusive bandage is used in combination with the drug. The absorption of topical betamethasone dipropionate is theoretically minuscule; however, if absorbed it follows the same pharmacokinetic profile as is typical of systemic corticosteroids. It is metabolized primarily by the liver by hydrolysis to its metabolites betamethasone 17-monopropionate (primary) and betamethasone and the 6β-hydroxy derivatives of those metabolites, and it is excreted primarily by the kidneys.
== Description == The Wound Man illustrates various injuries that a person might receive through war, accident, or disease: cuts and bruises from multiple weapons, rashes and pustules, thorn scratches, and the bites of venomous animals. The figure also includes some schematic anatomical outlines of several organs within his unusual, transparent abdomen.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.